Logo image of ALCRB.PA

CARBIOS (ALCRB.PA) Stock Fundamental Analysis

EPA:ALCRB - Euronext Paris - Matif - FR0011648716 - Common Stock - Currency: EUR

7.484  +0.48 (+6.85%)

Fundamental Rating

3

Overall ALCRB gets a fundamental rating of 3 out of 10. We evaluated ALCRB against 62 industry peers in the Chemicals industry. The financial health of ALCRB is average, but there are quite some concerns on its profitability. ALCRB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

ALCRB had negative earnings in the past year.
ALCRB had a negative operating cash flow in the past year.
In the past 5 years ALCRB reported 4 times negative net income.
In the past 5 years ALCRB always reported negative operating cash flow.
ALCRB.PA Yearly Net Income VS EBIT VS OCF VS FCFALCRB.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

ALCRB's Return On Assets of -11.21% is on the low side compared to the rest of the industry. ALCRB is outperformed by 74.19% of its industry peers.
ALCRB has a worse Return On Equity (-14.55%) than 70.97% of its industry peers.
Industry RankSector Rank
ROA -11.21%
ROE -14.55%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALCRB.PA Yearly ROA, ROE, ROICALCRB.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 30

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALCRB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALCRB.PA Yearly Profit, Operating, Gross MarginsALCRB.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

5

2. Health

2.1 Basic Checks

ALCRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALCRB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALCRB.PA Yearly Shares OutstandingALCRB.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
ALCRB.PA Yearly Total Debt VS Total AssetsALCRB.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of 0.95, we must say that ALCRB is in the distress zone and has some risk of bankruptcy.
ALCRB has a worse Altman-Z score (0.95) than 74.19% of its industry peers.
A Debt/Equity ratio of 0.17 indicates that ALCRB is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.17, ALCRB belongs to the best of the industry, outperforming 83.87% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Altman-Z 0.95
ROIC/WACCN/A
WACC7.44%
ALCRB.PA Yearly LT Debt VS Equity VS FCFALCRB.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 7.52 indicates that ALCRB has no problem at all paying its short term obligations.
ALCRB has a better Current ratio (7.52) than 96.77% of its industry peers.
A Quick Ratio of 7.45 indicates that ALCRB has no problem at all paying its short term obligations.
The Quick ratio of ALCRB (7.45) is better than 98.39% of its industry peers.
Industry RankSector Rank
Current Ratio 7.52
Quick Ratio 7.45
ALCRB.PA Yearly Current Assets VS Current LiabilitesALCRB.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

5

3. Growth

3.1 Past

ALCRB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.29%.
Looking at the last year, ALCRB shows a very strong growth in Revenue. The Revenue has grown by 466.67%.
ALCRB shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -37.71% yearly.
EPS 1Y (TTM)-0.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)466.67%
Revenue growth 3Y9.01%
Revenue growth 5Y-37.71%
Sales Q2Q%1475%

3.2 Future

Based on estimates for the next years, ALCRB will show a very strong growth in Earnings Per Share. The EPS will grow by 27.01% on average per year.
ALCRB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 300.17% yearly.
EPS Next Y1.82%
EPS Next 2Y8.12%
EPS Next 3Y6.49%
EPS Next 5Y27.01%
Revenue Next Year3724.84%
Revenue Next 2Y1099.31%
Revenue Next 3Y509.81%
Revenue Next 5Y300.17%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALCRB.PA Yearly Revenue VS EstimatesALCRB.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
ALCRB.PA Yearly EPS VS EstimatesALCRB.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

0

4. Valuation

4.1 Price/Earnings Ratio

ALCRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALCRB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALCRB.PA Price Earnings VS Forward Price EarningsALCRB.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALCRB.PA Per share dataALCRB.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.12%
EPS Next 3Y6.49%

0

5. Dividend

5.1 Amount

ALCRB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CARBIOS

EPA:ALCRB (4/28/2025, 7:00:00 PM)

7.484

+0.48 (+6.85%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)04-11 2025-04-11/amc
Earnings (Next)09-23 2025-09-23
Inst Owners23.25%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap126.11M
Analysts83.64
Price Target11.9 (59.01%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-44.44%
PT rev (3m)-48.72%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)5.36%
EPS NY rev (3m)5.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-23.34%
Revenue NY rev (3m)-23.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1637.73
P/FCF N/A
P/OCF N/A
P/B 0.58
P/tB 0.72
EV/EBITDA N/A
EPS(TTM)-1.97
EYN/A
EPS(NY)-2.22
Fwd EYN/A
FCF(TTM)-3.95
FCFYN/A
OCF(TTM)-1.52
OCFYN/A
SpS0
BVpS12.91
TBVpS10.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.21%
ROE -14.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 562.84%
Cap/Sales 53228.6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.52
Quick Ratio 7.45
Altman-Z 0.95
F-Score2
WACC7.44%
ROIC/WACCN/A
Cap/Depr(3y)437.01%
Cap/Depr(5y)449.88%
Cap/Sales(3y)53289.6%
Cap/Sales(5y)34828.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y1.82%
EPS Next 2Y8.12%
EPS Next 3Y6.49%
EPS Next 5Y27.01%
Revenue 1Y (TTM)466.67%
Revenue growth 3Y9.01%
Revenue growth 5Y-37.71%
Sales Q2Q%1475%
Revenue Next Year3724.84%
Revenue Next 2Y1099.31%
Revenue Next 3Y509.81%
Revenue Next 5Y300.17%
EBIT growth 1Y-27.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.29%
EBIT Next 3Y48.08%
EBIT Next 5Y33.42%
FCF growth 1Y-58.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.7%
OCF growth 3YN/A
OCF growth 5YN/A